Clinical trial
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
NCT00222144 · University of Kansas, Other · Completed
Key facts
| NCT number | NCT00222144 |
|---|---|
| Title | Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer |
| Lead sponsor | University of Kansas, Other |
| Collaborators | Novartis Industry Kansas Masonic Cancer Research Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Gleevec and Taxotere |
| Enrollment | 23 |
| Start date | Sep 1, 2004 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: